CURX · Curanex Pharmaceuticals Inc Common Stock

Curanex Pharmaceuticals Inc (CURX) posted FY 2025 operating income of -$4.2M and net income of -$4.2M, with diluted EPS of -$0.17. These results reflect the Company's strategic pivot to intensify research and development post-IPO, as higher operating expenses drove the losses. Management notes that the increase in cash used in operating activities—reaching -$10.5M—was primarily attributable to this expansion of R&D efforts following the August 2025 IPO completion and underwriters' over-allotment exercise in September.

The transition to public company status amplified these dynamics, balancing investment in core assets against near-term losses. Investors should note the going concern assessment's reliance on management's plans, including financing options, amid volatile biotech funding environments and potential short squeeze risks from low float. Overall, FY 2025 positioned Curanex with a fortified balance sheet to execute on R&D while navigating expense growth and liquidity horizons.